uniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 1,993 Shares

by · The Markets Daily

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Madhavan Balachandran sold 1,993 shares of uniQure stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the transaction, the director owned 43,254 shares in the company, valued at $1,170,453.24. The trade was a 4.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

uniQure Trading Up 2.8%

uniQure stock traded up $0.75 during midday trading on Friday, reaching $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The stock has a market capitalization of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock’s 50-day simple moving average is $22.31 and its 200 day simple moving average is $21.76.

uniQure (NASDAQ:QURE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. Analysts expect that uniQure N.V. will post -3.64 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of QURE. Woodline Partners LP lifted its stake in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of uniQure in the second quarter worth about $497,000. Marshall Wace LLP lifted its stake in shares of uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of uniQure in the second quarter worth about $540,000. Finally, Ameriprise Financial Inc. lifted its stake in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on QURE shares. Sanford C. Bernstein cut uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Chardan Capital boosted their price objective on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. HC Wainwright reduced their price objective on uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Barclays reduced their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

Get Our Latest Research Report on QURE

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.

Featured Articles